Cubist Pharmaceuticals could get up to $98.5 mil. from partners Bristol, Merck, Pfizer in best case -- IPO.
Executive Summary
CUBIST PHARMS COULD RECEIVE UP TO $98.5 MIL. FROM PARTNERS Bristol-Myers Squibb, Merck and Pfizer in research support payments, licensing fees, milestones and other payments if a successful drug candidate is commercialized from each of the programs in the collaborations, Cubist states in its prospectus for an initial public offering. The anti-infectives R&D firm entered into collaborations with Bristol and Merck in June and with Pfizer in December. Bristol made a $4 mil. equity investment in Cubist.